Guard Therapeutics International AB
5LH0
Company Profile
Business description
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
Contact
Scheelevagen 22
Lund223 63
SWET: +46 462865030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Earnings growth maintained despite turbulent market conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.10 | 57.40 | 0.64% |
| CAC 40 | 8,299.42 | 237.11 | 2.94% |
| DAX 40 | 24,918.69 | 516.99 | 2.12% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,438.66 | 219.55 | 2.15% |
| HKSE | 26,213.78 | 315.17 | 1.22% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,145.19 | 109.49 | 0.84% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,793.60 | 58.60 | 0.67% |
| SSE Composite Index | 4,160.17 | 48.01 | 1.17% |